Literature DB >> 24858721

Impact of venous thromboembolism on survival in patients with advanced cancer: an unmet clinical need.

Gary H Lyman1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24858721     DOI： 10.1007/s11739-014-1087-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  20 in total

1.  Use and misuse of population attributable fractions.

Authors:  B Rockhill; B Newman; C Weinberg
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

2.  Origin of deep vein thrombosis of the leg.

Authors:  A N Nicolaides; V V Kakkar; E S Field
Journal:  Bull Soc Int Chir       Date:  1973 Jan-Feb

3.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Authors:  A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

4.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

5.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.

Authors:  A A Khorana; C W Francis; E Culakova; N M Kuderer; G H Lyman
Journal:  J Thromb Haemost       Date:  2007-03       Impact factor: 5.824

6.  Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis.

Authors:  Gary H Lyman; Laurent Eckert; Yanxin Wang; Hongwei Wang; Alexander Cohen
Journal:  Oncologist       Date:  2013-11-08

7.  Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.

Authors:  P D Stein; J W Henry
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

8.  Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.

Authors:  Ourania Katopodis; Paul Ross; Andrew R Norman; Jacqui Oates; David Cunningham
Journal:  Eur J Cancer       Date:  2004-10       Impact factor: 9.162

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316
View more
  7 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

2.  Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.

Authors:  Melina Verso; Giancarlo Agnelli; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2015-04-04       Impact factor: 3.397

Review 3.  The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis.

Authors:  Kate Burbury; Michael P MacManus
Journal:  Clin Exp Metastasis       Date:  2018-02-28       Impact factor: 5.150

Review 4.  Mitigating acute chemotherapy-associated adverse events in patients with cancer.

Authors:  Nicole M Kuderer; Aakash Desai; Maryam B Lustberg; Gary H Lyman
Journal:  Nat Rev Clin Oncol       Date:  2022-10-11       Impact factor: 65.011

5.  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Authors:  Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello
Journal:  Blood Adv       Date:  2021-02-23

6.  Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.

Authors:  Ryan Pelletier
Journal:  J Oncol Pharm Pract       Date:  2021-03-24       Impact factor: 1.809

Review 7.  New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism.

Authors:  Kaidireyahan Wumaier; Wenqian Li; Jiuwei Cui
Journal:  Drug Des Devel Ther       Date:  2022-08-03       Impact factor: 4.319
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.